Strides plans for US growth

Earlier this year, Strides Pharma Science outlined plans to adopt a “recalibrated strategy” in the US, with a focus on launches through its own commercial front-end rather than through partners. As well as pledging to take up a “front-end bias” in the country, Strides had also said it would exit its partnership business and eschew new “partnership contracts” (Generics bulletin, 25 May 2018, page 5).